The DOI matches its Crossref record; 670 of the 670 references it cites were found in a registry or an index.
Harnessing innate immune pathways for therapeutic advancement in cancer
Open accessAbstract
The innate immune pathway is receiving increasing attention in cancer therapy. This pathway is ubiquitous across various cell types, not only in innate immune cells but also in adaptive immune cells, tumor cells, and stromal cells. Agonists targeting the innate immune pathway have shown profound changes in the tumor microenvironment (TME) and improved tumor prognosis in preclinical studies. However, to date, the clinical success of drugs targeting the innate immune pathway remains limited. Interestingly, recent studies have shown that activation of the innate immune pathway can paradoxically promote tumor progression. The uncertainty surrounding the therapeutic effectiveness of targeted drugs for the innate immune pathway is a critical issue that needs immediate investigation. In this review, we observe that the role of the innate immune pathway demonstrates heterogeneity, linked to the tumor development stage, pathway status, and specific cell types. We propose that within the TME, the innate immune pathway exhibits multidimensional diversity. This diversity is fundamentally rooted in cellular heterogeneity and is manifested as a variety of signaling networks. The pro-tumor effect of innate immune pathway activation essentially reflects the suppression of classical pathways and the activation of potential pro-tumor alternative pathways. Refining our understanding of the tumor’s innate immune pathway network and employing appropriate targeting strategies can enhance our ability to harness the anti-tumor potential of the innate immune pathway and ultimately bridge the gap from preclinical to clinical application.
Overview
The claims and statistics of this paper haven’t been checked yet.
Run the check — free, no account needed. It reads the open-access text and checks the sources it cites.
Integrity signals
Registry
Cites
Statistics
Verification
Claims the paper makes
The claims and statistics of this paper haven’t been checked yet.
Run the check — free, no account needed. It reads the open-access text and checks the sources it cites.
Self-check
Percentages, sums and reported differences re-computed from the paper’s own numbers.
The self-check needs the paper’s full text.
Citations
Cites
3 retracted
Singh, A. K., Praharaj, M., Lombardo, K. A., Yoshida, T., Matoso, A., Baras, A. S., Zhao, L., Srikrishna, G., Huang, J., Prasad, P., et al. (2022) · Nature Communications · doi:10.1038/s41467-022-28509-z · Cited by 108
RetractedBanerjee, S., Halder, K., Bose, A., Bhattacharya, P., Gupta, G., Mahapatra, S. K., Das, S., Chaudhuri, S., Majumdar, S. B., & Majumdar, S. (2011) · Carcinogenesis · doi:10.1093/carcin/bgr208 · Cited by 41
RetractedChen, X., Yu, M., Xu, W., Kun, P., Wan, W., Yuhong, X., Ye, J., Liu, Y., & Luo, J. (2022) · Oxidative Medicine and Cellular Longevity · doi:10.1155/2022/9049571 · Cited by 14
RetractedSuccinate is an inflammatory signal that induces IL-1β through HIF-1α
Tannahill, G. M., Curtis, A. M., Adamik, J., Palsson-McDermott, E. M., McGettrick, A. F., Goel, G., Frezza, C., Bernard, N. J., Kelly, B., Foley, N. H., et al. (2013) · Nature · doi:10.1038/nature11986 · Cited by 4,176
Self-citationThe Role of Tumoral FOXP3 on Cell Proliferation, Migration, and Invasion in Gastric Cancer
Zhang, L., Xu, J., Zhang, X., Zhang, Y., Wang, L., Huang, X., & Xu, Z. (2017) · Cellular Physiology and Biochemistry · doi:10.1159/000479442 · Cited by 4,088
Tumour-associated macrophages as treatment targets in oncology
Mantovani, A., Marchesi, F., Malesci, A., Laghi, L., & Allavena, P. (2017) · Nature Reviews Clinical Oncology · doi:10.1038/nrclinonc.2016.217 · Cited by 4,033
Immunotherapy of Diffuse Gliomas: Biological Background, Current Status and Future Developments
Grauer, O. M., Wesseling, P., & Adema, G. J. (2009) · Brain Pathology · doi:10.1111/j.1750-3639.2009.00315.x · Cited by 4,007
CpG motifs in bacterial DNA trigger direct B-cell activation
Krieg, A. M., Yi, A.-K., Matson, S., Waldschmidt, T. J., Bishop, G. A., Teasdale, R., Koretzky, G. A., & Klinman, D. M. (1995) · Nature · doi:10.1038/374546a0 · Cited by 3,508
Approaches to treat immune hot, altered and cold tumours with combination immunotherapies
Galon, J., & Bruni, D. (2019) · Nature Reviews Drug Discovery · doi:10.1038/s41573-018-0007-y · Cited by 3,409
Polarization of Tumor-Associated Neutrophil Phenotype by TGF-β: “N1” versus “N2” TAN
Fridlender, Z. G., Sun, J., Kim, S., Kapoor, V., Cheng, G., Ling, L., Worthen, G. S., & Albelda, S. M. (2009) · Cancer Cell · doi:10.1016/j.ccr.2009.06.017 · Cited by 3,371
Cited by
Huynh, T. M. H., Huang, P.-X., Wang, K.-L., Tran, N.-T., Iao, H. M., Pan, W.-C., Chang, Y.-H., Lien, H.-W., Lee, A. Y.-L., Chou, T.-C., et al. (2025) · ACS Nano · doi:10.1021/acsnano.5c05395 · Cited by 122
Neutrophils and Neutrophil-Based Drug Delivery Systems in Anti-Cancer Therapy
Wahnou, H., El Kebbaj, R., Hba, S., Ouadghiri, Z., El Faqer, O., Pinon, A., Liagre, B., Limami, Y., & Duval, R. E. (2025) · Cancers · doi:10.3390/cancers17071232 · Cited by 35
Immunogenic cell death mediated TLR3/4-activated MSCs in U87 GBM cell line
Emami Meybodi, S. M., Moradi Moraddahande, F., & Dehghani Firoozabadi, A. (2024) · Heliyon · doi:10.1016/j.heliyon.2024.e29858 · Cited by 3
Metadata
- Authors
- Hu, A., Sun, L., Lin, H., Liao, Y., Yang, H., & Mao, Y.
- Venue
- Signal Transduction and Targeted Therapy
- Published
- 2024-03-25
- Volume
- 9
- Issue
- 1
- Pages
- 68-68
- ISSN
- 2059-3635 (ISSN-L)
- OpenAlex
- W4394738965
- Cited by
- 255
- References
- 670
- FWCI
- 38.98
- Type
- journal article
- Language
- en
- Open access
- gold
About these checks
Registry, retraction, Cites and statistics results are computed, not judged, with one exception: a printed reference that no index lists is read once by a model before it counts as a citation error. Claims are extracted by a model and kept only when their quote appears verbatim in the text; each cited source is then checked, with a model’s help, for whether it says what the claim relies on. Those verdicts can be wrong — read the claim’s quote and the cited source before relying on one.
Statistics and arithmetic are recomputed, not judged.
Confidence bands are shown only for fields calibrated on our annotated test set. None is calibrated yet, so no band is shown.
What counts as a claim ›How we measure confidence ›How we check this ›
Are you an author, or do you see a problem with this page? Request a review
How to cite
Cite CoChat for the checks on this page, and the paper for its own findings.
- This page
- CoChat. (2026). Citation check: Harnessing innate immune pathways for therapeutic advancement in cancer. https://app.cochat.ai/papers/10.1038/s41392-024-01765-9
- The paper
- Hu, A., Sun, L., Lin, H., Liao, Y., Yang, H., & Mao, Y. (2024). Harnessing innate immune pathways for therapeutic advancement in cancer. Signal Transduction and Targeted Therapy. https://doi.org/10.1038/s41392-024-01765-9
Data sources
Bibliographic data: Semantic Scholar, OpenAlex, Crossref.
Contains information from the Semantic Scholar Academic Graph Datasets, made available under the ODC Attribution License (ODC-BY 1.0).
Semantic Scholar’s data is described in: Kinney, R., et al. (2023). The Semantic Scholar Open Data Platform. arXiv:2301.10140.